Novo Nordisk’s mAb for MACE risk reduction fails in Phase III trial
Novo Nordisk’s monoclonal antibody (mAb) designed to reduce the risk of major adverse cardiovascular events (MACE) in patients…
Novo Nordisk to seek oral sickle cell therapy approval after Phase III victory
A Phase III trial of Novo Nordisk’s once-daily tablet has met both co-primary endpoints, reducing vaso-occlusive crises (VOC)…
Novo Nordisk downgraded by leading banks as CagriSema trial flops against Zepbound
Novo Nordisk downgraded by leading banks as CagriSema trial flops against Zepbound Proactive uses images sourced from Shutterstock…
Novo Nordisk downgraded by leading banks as CagriSema trial flops against Zepbound
Novo Nordisk downgraded by leading banks as CagriSema trial flops against Zepbound Proactive uses images sourced from Shutterstock…